Mizuho raised the firm’s price target on Apogee Therapeutics (APGE) to $110 from $105 and keeps an Outperform rating on the shares. The firm cites last week’s 52-week data for zumilokibart in atopic dermatitis for the target boost. The analyst increased Apogee’s probability of success in atopic dermatitis and also factored in Apogee’s recent follow-on offering.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics Prices Upsized Public Equity Offering
- Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
- Apogee Therapeutics 5M share Secondary priced at $70.00
- Apogee Therapeutics price target raised to $118 from $108 at Deutsche Bank
- Apogee Therapeutics price target raised to $160 from $130 at Guggenheim